SCHEMBL770284

SCHEMBL770284

COc1ccccc1N1CCN(C(=O)CCCC(=O)N2CCCC3CCCC=C32)CC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
RAB9A P51151 2/20 0.51
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 3/20 0.48
HTR1A P08908 3/20 0.48
HTR7 P34969 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
DRD2 P14416 1/20 0.48
GAA P10253 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770749 0.96 L3MBTL1 (0.56) L3MBTL1RAB9ATSHRALDH1A1KDM4E
SCHEMBL769469 0.90 RAB9A (0.52) L3MBTL1RAB9ATSHRALDH1A1KDM4E
SCHEMBL770907 0.87 AR (0.54) RAB9AMAPTTSHRALDH1A1LMNA
SCHEMBL769756 0.85 AR (0.54) RAB9AMAPTTSHRALDH1A1LMNA
SCHEMBL770999 0.85 PKM (0.51) RAB9ATSHRALDH1A1KDM4ETDP1
SCHEMBL770676 0.85 L3MBTL1 (0.48) L3MBTL1RAB9AMAPTTSHRALDH1A1
SCHEMBL769689 0.84 L3MBTL1 (0.53) L3MBTL1RAB9AMAPTTSHRALDH1A1
SCHEMBL770467 0.83 KMT2A (0.61) L3MBTL1RAB9AMAPTTSHRALDH1A1
SCHEMBL770700 0.83 AR (0.51) RAB9AMAPTTSHRALDH1A1KMT2A
SCHEMBL771534 0.80 L3MBTL1 (0.57) L3MBTL1RAB9ATSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 L3MBTL1 4097/4885RAB9A 2187/4885MAPT 618/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 L3MBTL1 4090/4885RAB9A 2217/4885MAPT 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.